… As of 31st December 2013, 36 clinical studies, including clinical pharmacology (CP), phase
… phase III studies, have either been completed or are ongoing. A total of 2428 patients were …

… one year) to oxaliplatin-based standard adjuvant chemotherapy in … treated in two ongoing,
dose-escalating phase I studies. … biomarker for defining the pharmacological response and the …

… for refractory and relapsed cases with poor prognosis are still … blood cancer more common
in children than adults, … cells were highly sensitive to pharmacological inactivation of CDK1 by …

… The prognosis for patients with recurrent GBM remains poor, … A dose-escalating scheme was
used with a gradual increase of … adult patients with GBM received a combination treatment (…

… In a study that investigated Oxaliplatin, it was observed that platinum-DNA adduct levels in …
We hypothesize that the previously reported poor stability of this adduct in DNA [23] makes its …

… poor prognosis of CSS in Stage III and Stage IV CRC patients. … were treated with bevacizumab
and oxaliplatin or irinotecan… Early-life obesity and adulthood colorectal cancer risk: a meta-…

… stage IV melanoma patients are vaccinated with mature DC … In this study, EBV is more
frequently associated with poor … Design: Phase I, open-label, dose-escalating study of a single 10 …

… Several dietary and pharmacological interventions have … BCAT2 and BCKDHA knockdown
impaired pancreatic cancer … with chemotherapy (capecitabine plus oxaliplatin) [254]. PEG-…

… structures would improve their pharmacological properties, namely … with tumor aggressiveness
and a poor prognosis [59]. … the adult isoform, ie, isoform PKM1, in the human cancer cell …

… , dose-escalating, open-label, multi-center study being … Biliary tract cancer (BTC) is an
aggressive malignancy with a poor … Our group has developed mature technologies for each of …